INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Tax withholdingVerified data

Trotta Matteo reported INCY

EVP, GM, Dermatology US · INCYTE CORP · Common Stock

Side
F
Value
$50K
Shares
537
Price
$92.23
Executed
Mar 25, 2026
Disclosed
Mar 26, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Mar 25 executedMar 26, 2026 disclosed

INCY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$50K reported value · 3.7% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · INCY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Tax withholding
    		F$54K
    463 sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    16
    GH
    Gardner David HEVP, Chief Strategy Officer
    INCYINCYTE CORP
    Tax withholding
    		F$117K
    920 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BK
    Basi Ramitpal KEVP, Human Resources
    INCYINCYTE CORP
    Tax withholding
    		F$65K
    504 sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M—
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M$235K
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    7
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$274K
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    11
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Tax withholding
    		F$41K
    350 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Tax withholding
    		F$56K
    477 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    0
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M—
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$264K
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    2
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M$221K
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    8
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$200K
    2,051 sh
    		May 26, 2026May 28, 2026
    traded May 26, 2026
    		+2dSEC FORM 4

    Evidence

    5
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Tax withholding
    		F$11K
    111 sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    15
    TM
    Trotta MatteoEVP, GM, Dermatology US
    INCYINCYTE CORP
    Grant or award
    		A—
    8,542 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    IK
    Issa Mohamed KhairieEVP, Head of US Oncology
    INCYINCYTE CORP
    Grant or award
    		A—
    14.2K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    5
    MJ
    Morrissey Michael JamesEVP, Head of Tech. Operations
    INCYINCYTE CORP
    Tax withholding
    		F$44K
    429 sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    19
    MJ
    Morrissey Michael JamesEVP, Head of Tech. Operations
    INCYINCYTE CORP
    Grant or award
    		A—
    7,426 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    19
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Grant or award
    		A—
    8,911 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Grant or award
    		A—
    4,218 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Grant or award
    		A—
    2,425 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002015975-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 25, 2026
    Published
    Mar 26, 2026
    Ingested by INSIDER
    Nov 5, 04:09 UTC
    Last re-read
    Nov 5, 04:09 UTC

    Extracted facts

    Filer
    Trotta Matteo
    Role
    EVP, GM, Dermatology US
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    INCYTE CORP
    Ticker
    INCY
    Shares
    537
    Price per share
    $92.23
    Value
    $49,528
    Execution date (reported)
    Mar 25, 2026
    Owned after transaction
    14.9K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 537
    • Price: $92.23

    = $49,528

    What this establishes

    Trotta Matteo filed this Form 4 reporting a tax withholding of INCY on Mar 25, 2026. It became public on Mar 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, GM, Dermatology US
    Trotta Matteocik:0002015975
    Issuer
    INCYTE CORPcik:0000879169

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.